Literature DB >> 24997607

Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.

Feng Mei1, Stephen P J Fancy1,2, Yun-An A Shen1, Jianqin Niu3, Chao Zhao4, Bryan Presley5, Edna Miao1, Seonok Lee1, Sonia R Mayoral1, Stephanie A Redmond1, Ainhoa Etxeberria1, Lan Xiao3, Robin J M Franklin4, Ari Green1, Stephen L Hauser1, Jonah R Chan1.   

Abstract

Functional screening for compounds that promote remyelination represents a major hurdle in the development of rational therapeutics for multiple sclerosis. Screening for remyelination is problematic, as myelination requires the presence of axons. Standard methods do not resolve cell-autonomous effects and are not suited for high-throughput formats. Here we describe a binary indicant for myelination using micropillar arrays (BIMA). Engineered with conical dimensions, micropillars permit resolution of the extent and length of membrane wrapping from a single two-dimensional image. Confocal imaging acquired from the base to the tip of the pillars allows for detection of concentric wrapping observed as 'rings' of myelin. The platform is formatted in 96-well plates, amenable to semiautomated random acquisition and automated detection and quantification. Upon screening 1,000 bioactive molecules, we identified a cluster of antimuscarinic compounds that enhance oligodendrocyte differentiation and remyelination. Our findings demonstrate a new high-throughput screening platform for potential regenerative therapeutics in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24997607      PMCID: PMC4830134          DOI: 10.1038/nm.3618

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  27 in total

1.  Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.

Authors:  Clare E Buckley; Anita Marguerie; Alan G Roach; Paul Goldsmith; Angeleen Fleming; Wendy K Alderton; Robin J M Franklin
Journal:  Neuropharmacology       Date:  2010-05-05       Impact factor: 5.250

2.  Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells.

Authors:  G Wolswijk
Journal:  J Neurosci       Date:  1998-01-15       Impact factor: 6.167

3.  Control of myelin formation by axon caliber (with a model of the control mechanism).

Authors:  R L Friede
Journal:  J Comp Neurol       Date:  1972-02       Impact factor: 3.215

4.  Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation.

Authors:  Federica De Angelis; Antonietta Bernardo; Valerio Magnaghi; Luisa Minghetti; Ada Maria Tata
Journal:  Dev Neurobiol       Date:  2012-05       Impact factor: 3.964

5.  Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord.

Authors:  H S Keirstead; J M Levine; W F Blakemore
Journal:  Glia       Date:  1998-02       Impact factor: 7.452

6.  A rapid and reproducible assay for modeling myelination by oligodendrocytes using engineered nanofibers.

Authors:  Seonok Lee; S Y Christin Chong; Samuel J Tuck; Joseph M Corey; Jonah R Chan
Journal:  Nat Protoc       Date:  2013-04       Impact factor: 13.491

7.  Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS.

Authors:  Stephen P J Fancy; Sergio E Baranzini; Chao Zhao; Dong-In Yuk; Karen-Amanda Irvine; Sovann Kaing; Nader Sanai; Robin J M Franklin; David H Rowitch
Journal:  Genes Dev       Date:  2009-06-10       Impact factor: 11.361

8.  Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination.

Authors:  S Y Christin Chong; Sheila S Rosenberg; Stephen P J Fancy; Chao Zhao; Yun-An A Shen; Angela T Hahn; Aaron W McGee; Xiaomei Xu; Binhai Zheng; Li I Zhang; David H Rowitch; Robin J M Franklin; Q Richard Lu; Jonah R Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

9.  Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination.

Authors:  Stephen P J Fancy; Emily P Harrington; Tracy J Yuen; John C Silbereis; Chao Zhao; Sergio E Baranzini; Charlotte C Bruce; Jose J Otero; Eric J Huang; Roel Nusse; Robin J M Franklin; David H Rowitch
Journal:  Nat Neurosci       Date:  2011-06-26       Impact factor: 24.884

10.  A culture system to study oligodendrocyte myelination processes using engineered nanofibers.

Authors:  Seonok Lee; Michelle K Leach; Stephanie A Redmond; S Y Christin Chong; Synthia H Mellon; Samuel J Tuck; Zhang-Qi Feng; Joseph M Corey; Jonah R Chan
Journal:  Nat Methods       Date:  2012-07-15       Impact factor: 28.547

View more
  185 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

2.  A novel myelin protein zero transgenic zebrafish designed for rapid readout of in vivo myelination.

Authors:  Marnie A Preston; Lisbet T Finseth; Jennifer N Bourne; Wendy B Macklin
Journal:  Glia       Date:  2019-01-09       Impact factor: 7.452

3.  Muscarinic Receptor M3R Signaling Prevents Efficient Remyelination by Human and Mouse Oligodendrocyte Progenitor Cells.

Authors:  R Ross Welliver; Jessie J Polanco; Richard A Seidman; Anjali K Sinha; Melanie A O'Bara; Zainab M Khaku; Diara A Santiago González; Akiko Nishiyama; Jurgen Wess; M Laura Feltri; Pablo M Paez; Fraser J Sim
Journal:  J Neurosci       Date:  2018-06-29       Impact factor: 6.167

Review 4.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

Review 5.  Nanomaterial applications in multiple sclerosis inflamed brain.

Authors:  Clara Ballerini; Giovanni Baldi; Alessandra Aldinucci; Pietro Maggi
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-24       Impact factor: 4.147

Review 6.  Electrophysiological properties of NG2(+) cells: Matching physiological studies with gene expression profiles.

Authors:  Valerie A Larson; Ye Zhang; Dwight E Bergles
Journal:  Brain Res       Date:  2015-09-15       Impact factor: 3.252

Review 7.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

8.  Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Savina Apolloni; Paola Fabbrizio; Chiara Parisi; Susanna Amadio; Cinzia Volonté
Journal:  Mol Neurobiol       Date:  2014-12-09       Impact factor: 5.590

9.  Enhancing Oligodendrocyte Myelination Rescues Synaptic Loss and Improves Functional Recovery after Chronic Hypoxia.

Authors:  Fei Wang; Yu-Jian Yang; Nian Yang; Xian-Jun Chen; Nan-Xin Huang; Jun Zhang; Yi Wu; Zhi Liu; Xing Gao; Tao Li; Guang-Qiang Pan; Shu-Bao Liu; Hong-Li Li; Stephen P J Fancy; Lan Xiao; Jonah R Chan; Feng Mei
Journal:  Neuron       Date:  2018-08-02       Impact factor: 17.173

10.  Cell Type-Specific Intralocus Interactions Reveal Oligodendrocyte Mechanisms in MS.

Authors:  Daniel C Factor; Anna M Barbeau; Kevin C Allan; Lucille R Hu; Mayur Madhavan; An T Hoang; Kathryn E A Hazel; Parker A Hall; Sagar Nisraiyya; Fadi J Najm; Tyler E Miller; Zachary S Nevin; Robert T Karl; Bruna R Lima; Yanwei Song; Alexandra G Sibert; Gursimran K Dhillon; Christina Volsko; Cynthia F Bartels; Drew J Adams; Ranjan Dutta; Michael D Gallagher; William Phu; Alexey Kozlenkov; Stella Dracheva; Peter C Scacheri; Paul J Tesar; Olivia Corradin
Journal:  Cell       Date:  2020-04-03       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.